SCHEMBL1089643

SCHEMBL1089643

CC(=O)OCc1ccc(CN2CC(Nc3nccc(N4CCCCCC4)n3)C2)o1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.50
HRH4 Q9H3N8 5/20 0.41
CCNK O75909 2/20 0.41
CDK12 Q9NYV4 2/20 0.41
JAK2 O60674 2/20 0.39
FLT3 P36888 2/20 0.39
ACACB O00763 1/20 0.39
NFKB1 P19838 2/20 0.37
NR2C2 P49116 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
TAB1 Q15750 2/20 0.37
MAPK8 P45983 3/20 0.37
KDM4E B2RXH2 1/20 0.36
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
MRGPRX1 Q96LB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1090455 0.85 CXCR4 (0.57) CXCR4HRH4CCNKCDK12MAPK8
SCHEMBL1091346 0.85 CXCR4 (0.57) CXCR4HRH4CCNKCDK12MAPK8
SCHEMBL1090530 0.83 CXCR4 (0.57) CXCR4HRH4CCNKCDK12MAPK8
SCHEMBL1090657 0.77 CXCR4 (0.61) CXCR4HRH4CCNKCDK12MAPK8
SCHEMBL1091099 0.77 CXCR4 (0.62) CXCR4HRH4CCNKCDK12JAK2
SCHEMBL1090518 0.76 CXCR4 (0.54) CXCR4HRH4MRGPRX1
SCHEMBL1090419 0.76 CXCR4 (0.61) CXCR4HRH4CCNKCDK12JAK2
SCHEMBL1090654 0.76 CXCR4 (0.69) CXCR4HRH4CCNKCDK12MAPK8
SCHEMBL1090187 0.75 CXCR4 (0.57) CXCR4HRH4MAPK8KDM4E
SCHEMBL1090043 0.75 CXCR4 (0.59) CXCR4HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH4 130/4885CCNK 793/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH4 130/4885CCNK 793/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH4 130/4885CCNK 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.